| 6/3/2025 | EMGNHYLM | Teva prices, gives early results of six-series tender offer, ups caps
|
| 6/3/2025 | EMGNHYLM | Teva gives early results of six-series tender offer, ups caps
|
| 5/22/2025 | EMGNHYLM | Teva ups tender cap for six-series offer to $2.25 billion
|
| 5/20/2025 | EMHY | New Issue: Teva Pharmaceutical sells $1.2 billion and €1 billion notes in three tranches
|
| 5/20/2025 | EMHY | Teva Pharmaceutical sets talk in $2 billion three-part notes offering; books close Tuesday
|
| 5/19/2025 | BKEMGNHY | S&P gives Teva Pharmaceuticals notes BB
|
| 5/19/2025 | EMHY | Teva Pharmaceutical starts roadshow for $2 billion equivalent three-part bullet notes
|
| 5/19/2025 | EMGNHYLM | Teva offers to buy notes from six series for up to $2 billion
|
| 3/13/2023 | EMHYLM | Teva gives results, ups caps in offer for $2.5 billion of notes
|
| 3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
| 3/1/2023 | EMGNHY | New Issue: Teva prices upsized $2.49 billion equivalent sustainability notes in four tranches
|
| 3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
| 3/1/2023 | EMGNHY | Teva upsizes to $2.49 billion, hones talk on four-part notes offering; pricing Wednesday
|
| 2/28/2023 | EMGNHY | Moody's assigns Ba2 to Teva notes
|
| 2/28/2023 | EMGNHY | Teva sets talk in $2.06 billion four-part sustainability-linked notes offering; pricing Wednesday
|
| 2/27/2023 | EMHYLM | Teva starts tender offer for $2.25 billion of notes due 2023 to 2026
|
| 2/27/2023 | EMGNHY | Teva starts roadshow for $2.06 billion four-part offering of sustainability-linked notes
|
| 2/24/2023 | EMHY | Israel’s Teva sets non-deal roadshow via Citigroup and Goldman Sachs in week ahead
|
| 11/10/2021 | EMHYLM | Teva gives early tender results for six series, lifts cap to $4 billion
|
| 10/27/2021 | EMHYLM | Teva Pharmaceutical commences capped cash tender offer for six series of notes
|
| 10/27/2021 | EMHY | S&P assigns Teva notes BB-
|
| 10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes; pricing expected Tuesday
|
| 10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes
|
| 10/27/2021 | EMHY | Moody's rates Teva notes Ba2
|
| 11/21/2019 | EMHYLM | Teva Pharmaceutical to redeem €650 million of 3/8% notes
|
| 11/19/2019 | EMHY | New Issue: Teva Pharmaceutical prices $1 billion 7 1/8% notes and €1 billion 6% notes at par
|
| 11/19/2019 | EMHY | Teva Pharmaceutical upsizes bond tranches, tightens talk amid huge demand; pricing Tuesday
|
| 11/19/2019 | EMHY | Teva Pharmaceutical ups bond tranches to $1 billion and €1 billion, tightens talk; pricing Tuesday
|
| 11/18/2019 | EMHY | Teva sets tranches, talk for upsized $2 billion equivalent long five-year dual-currency notes
|
| 11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
| 4/11/2019 | BKCVEMIG | Fitch rates Teva loan BB
|
| 3/16/2018 | BKCVEMIG | Fitch rates Teva Pharmaceutical notes BB/RR4
|
| 3/1/2018 | BKCVEMIG | Fitch rates Teva notes BB
|
| 2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
| 2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
| 7/20/2016 | EM | New Issue: Israel’s Teva Pharmaceutical Finance prices €4 billion of notes in three tranches
|
| 7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
| 7/20/2016 | EM | Israel’s Teva Pharmaceutical Finance Netherlands offers euro-denominated notes in three parts
|
| 7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
| 3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
| 3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
| 3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
